A Double-Masked, Randomized, Single-Center Study Evaluating the Safety and Efficacy of 0.1% Thymosin beta 4 Ophthalmic Solution Compared to Vehicle on the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model

Trial Profile

A Double-Masked, Randomized, Single-Center Study Evaluating the Safety and Efficacy of 0.1% Thymosin beta 4 Ophthalmic Solution Compared to Vehicle on the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2015

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors RegeneRx Biopharmaceuticals
  • Most Recent Events

    • 22 May 2015 Results published in a RegeneRx Biopharmaceuticals media release.
    • 22 May 2015 According to a RegeneRx Biopharmaceuticals media release, data from this study were published in Clinical Ophthalmology.
    • 10 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top